Guggenheim initiated coverage on Xilio Therapeutics with a new price target
$XLO
Biotechnology: Pharmaceutical Preparations
Health Care
Guggenheim initiated coverage of Xilio Therapeutics with a rating of Buy and set a new price target of $40.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/21/2022 | $7.00 | Buy | Chardan Capital Markets |
| 1/10/2022 | $36.00 | Buy | HC Wainwright & Co. |
| 11/16/2021 | $40.00 | Buy | Guggenheim |
| 11/16/2021 | $31.00 | Outperform | Raymond James |
| 11/16/2021 | Outperform | Cowen & Co. | |
| 11/16/2021 | $32.00 | Overweight | Morgan Stanley |